ARO BIOTHERAPEUTICS
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
ARO BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.arobiotx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
166.5 M USD
Technology used in webpage:
Domain Not Resolving Euro U.S. Server Location
Similar Organizations
Frontier Medicines
Frontier Medicines is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery.
GRO Biosciences
GRO Biosciences is a biotechnology company that expands the amino acid alphabet to overcome the limitations of protein therapeutics.
JOGO Health
JOGO Health is a biotech company focused on digital therepeutics for neuromuscular conditions.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Schrödinger
Schrödinger develops molecular design software for pharma/biotech and materials research, and is advancing a drug discovery pipeline.
Silk Road Medical
Silk Road Medical provides research and development services of medical devices for neurovascular diseases.
SmartCella
SmartCella is an innovative biotechnology and medtech company.
Sword Health
Sword Health offers digital physical therapy programs with AI coaching to help people recover from pain and avoid surgery.
Valneva
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Aro Biotherapeutics
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC investment in Series B - Aro Biotherapeutics
HealthCap
HealthCap investment in Series B - Aro Biotherapeutics
Northpond Ventures
Northpond Ventures investment in Series B - Aro Biotherapeutics
BVF Partners
BVF Partners investment in Series B - Aro Biotherapeutics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Aro Biotherapeutics
Northpond Ventures
Northpond Ventures investment in Series A - Aro Biotherapeutics
HealthCap
HealthCap investment in Series A - Aro Biotherapeutics
Johnson & Johnson Robotics and Digital Solutions
Johnson & Johnson Robotics and Digital Solutions investment in Series A - Aro Biotherapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Series A - Aro Biotherapeutics
Official Site Inspections
http://www.arobiotx.com Semrush global rank: 6.65 M Semrush visits lastest month: 1.05 K
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Aro Biotherapeutics"
About Us | Aro Biotherapeutics - ARO Live
At Aro, we’re developing a patented platform technology called Centyrins that are uniquely positioned to achieve precise targeting of diverse therapeutic payloads to specific cells of interest.See details»
Leadership | Aro Biotherapeutics - ARO Live
The Aro leadership team has a proven track record across drug discovery, development and commercializationSee details»
Aro Biotherapeutics - Crunchbase Company Profile
Contact Email [email protected] Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious …See details»
Aro Biotherapeutics - LinkedIn
Aro Biotherapeutics | 4,880 followers on LinkedIn. | Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development ...See details»
Aro Biotherapeutics - Overview, News & Similar companies
Nov 28, 2023 www.arobiotx.com. Revenue <$5 Million. Industry Business Services General Business Services . Most Recent Scoops. Nov 28 2023. Funding. Sep 7 2021. Facilities …See details»
Aro Biotherapeutics Receives FDA Orphan Drug …
The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For …See details»
Aro Biotherapeutics Company Profile 2024: Valuation, …
Aro Biotherapeutics General Information Description. Developer of a protein drug platform designed to unlock the potential of genetic medicines. The company's drugs are small, non-antibody protein scaffolds that can be expressed as multi …See details»
Aro Biotherapeutics Expands Leadership Team with Addition of …
Feb 23, 2021 Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that Adam Dinerman, Ph.DSee details»
Aro Biotherapeutics Expands Leadership Team and Plans Move to …
Aug 4, 2021 The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific …See details»
Aro Biotherapeutics Company Overview, Contact Details
Arobiotx partners with Allocated Bullion Exchange Ltd. Aro Biotherapeutics announces start of first in human study with ABX1100, a novel first in class Centyrin-siRNA conjugate in development …See details»
Aro Biotherapeutics Expands Leadership Team and Plans Move to …
Philadelphia, PA, August 4, 2021 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the appointment of three …See details»
Aro Biotherapeutics Expands its Leadership Team - ARO Live
The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of …See details»
Aro Biotherapeutics Announces Start of First in Human Study with ...
Oct 25, 2023 For more information, visit www.arobiotx.com. Contacts. Mike Beyer Sam Brown Inc. [email protected] 312-961-2502 Contacts. Mike Beyer Sam Brown Inc. …See details»
Aro Biotherapeutics Expands Leadership Team and Plans Move
Aug 4, 2021 They both have deep experience in their respective functional areas that will bring great value to our organization. In his expanded role, Scott and his team will help us build …See details»
Aro Biotherapeutics Expands Leadership Team and Plans Move to …
Aug 4, 2021 “ The expansion of our leadership team provides Aro with proven executive expertise as we advance our first molecules toward clinical development and continue to scale …See details»
Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation …
Sep 15, 2022 For more information, visit www.arobiotx.com. Contacts. Mike Beyer Sam Brown Inc. [email protected] 312-961-2502 Contacts. Mike Beyer Sam Brown Inc. …See details»
Aro Biotherapeutics Highlight Therapeutic Potential of Centyrin ...
May 11, 2022 The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific …See details»
Aro Biotherapeutics Secures $41.5M Series B Financing
Nov 28, 2023 For more information, visit www.arobiotx.com. Contacts. Mike Beyer Sam Brown Inc. [email protected] 312-961-2502 Contacts. Mike Beyer Sam Brown Inc. …See details»
Aro Biotherapeutics Expands its Leadership Team - ARO Live
Feb 23, 2021 The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific …See details»